The company was founded in 1956, issued A-shares and listed in 2000, and is a state-owned listed company. After more than 60 years of development, Haizheng Pharmaceutical has become a comprehensive pharmaceutical enterprise group integrating the entire value chain of research, production and marketing, and vertical integration of APIs and formulations. The company is a comprehensive pharmaceutical enterprise integrating the entire value chain of research, production and marketing, integrating APIs and formulations, and developing in multiple regions. It focuses on the development of multiple industries such as chemical medicine, biopharmaceuticals, veterinary medicine, traditional Chinese medicine and pharmaceutical commerce, and accelerates the layout of emerging markets such as the health industry and health aesthetics. The company's main products are: doractin, methylprednisolone sodium succinate for injection, piperacillin sodium and tazobactam sodium for injections, amlodipine atorvastatin calcium tablets, etc. Corporate honors: It has won honors such as “National High-tech Enterprise” and “National May 1st Labor Award”, and has been selected for honorary titles such as the country's first batch of “Innovative Enterprises”, “National Intellectual Property Demonstration Enterprise”, and the Zhejiang Provincial Government Quality Award.
No Data